Ayurvedic medication in the treatment of Irritable Bowel Syndrome

“Effect of Kalingadi Churna (in constipation predominant) and Dadimastaka Churna (in diarrhea predominant) in Irritable Bowel Syndrome –A Randomized Controlled Clinical Trial ?

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/12/048261

Enrollment

Registered

2022-12-19

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K581- Irritable bowel syndrome with constipation Health Condition 2: K580- Irritable bowel syndrome with diarrhea

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Individuals between the age group of 20 to 60 years patients of either sex subjects fulfilling the diagnostic Rome 4 criteria

Exclusion criteria

Exclusion criteria: Other subtypes of IBS like mixed and unclassified Diagnosed with Inflammatory bowel disorders Known case of CA colon, Intestinal tuberculosis Patients with chronic alcoholism Patients with any co-morbidities needs long term drug treatment, rheumatoid arthritis, tuberculosis, uncontrolled diabetes, HTN, etc. Pregnant or lactating women . Patient have an allergic reaction to Mebeverine in the past. Patients on any medications for the management of IBS in the last 30 days

Design outcomes

Primary

Measure	Time frame
IBS Adequate Relief IBS symptom severity scoreTimepoint: 60 days	—

Secondary

Measure	Time frame
Gastrointestinal Symptom Rating Scale (GSRS) IBS –Visual Analogue Scale (IBS-VAS) Complete Spontaneous Bowel Movements (CSBMs) Bristol Stool Form (BSF) Hamilton Anxiety Rating scale Hamilton Depression Rating scale IBS quality of life (IBS–Qol) Stool Examination, Interleukin -6 (IL-6) Timepoint: GSRS,IBS-VAS,CSBMs,BSF, Hamilton Anxiety Rating scale ,Hamilton Depression Rating scale & IBS-Qol on baseline 15th 30th 45th 60th day . Stool Examination & Interleukin 6 on baseline & 60th day	—

Measure

Time frame

Gastrointestinal Symptom Rating Scale (GSRS) IBS –Visual Analogue Scale (IBS-VAS) Complete Spontaneous Bowel Movements (CSBMs) Bristol Stool Form (BSF) Hamilton Anxiety Rating scale Hamilton Depression Rating scale IBS quality of life (IBS–Qol) Stool Examination, Interleukin -6 (IL-6) Timepoint: GSRS,IBS-VAS,CSBMs,BSF, Hamilton Anxiety Rating scale ,Hamilton Depression Rating scale & IBS-Qol on baseline 15th 30th 45th 60th day . Stool Examination & Interleukin 6 on baseline & 60th day

—

Countries

India

Contacts

Public ContactDr Basavaraj R Tubaki

KAHERs Shri BMK Ayurveda Mahavidhyalaya shahpur Belgavi

ayurbasavaraj@gmail.com9448634660

Outcome results